KEY CHARACTERISTICS • Meets critical need for thermal weldability and kink resistance • Minimizes extractables during processing • Provides excellent tensile strength • Complies with USP VI and ISO 10993-4, -5, -11 certifications • Suitable for gamma and autoclave sterilization methods • Bio-based grade option formulated with nearly 40% Gen 1 biomass content PRODUCT OVERVIEW 1.844.4AVIENT www.avient.com Copyright © 2023, Avient Corporation.

e-Certificate of registration Swedish Companies Registration Office BRANCH D1a- 6858922 Registration number Date of registration of the company Document created on Date of registration of current name Page 516411-5031 2018-08-28 2021-11-30 17:11 2021-11-29 1 (3) Pending matter(s) The register indicates pending matter(s) regarding a change to the registered information at the time this certificate was created. e-Certificate of registration Swedish Companies Registration Office BRANCH D1a- 6858922 Registration number Date of registration of the company Document created on Date of registration of current name Page 516411-5031 2018-08-28 2021-11-30 17:11 2021-11-29 2 (3) Registration number: 516411-5031 Business name: Avient S.à r.l., Sweden Filial Address: Drottninggatan 56 411 07 GÖTEBORG County and municipality: Västra Götaland, Göteborg Note: MANAGING DIRECTOR 630516 Palm, Christoph, Gruss Strooss 35, L-9991 WEISWAMPACH, LUXEMBURG AUDITORS 556053-5873 Ernst & Young Aktiebolag, Box 7850, 103 99 STOCKHOLM Represented by: 850807-5135 PRINCIPALLY RESPONSIBLE AUDITOR 850807-5135 Edman, Mikael Thomas Gunnar, c/o Ernst & Young AB, 401 82 GÖTEBORG SIGNATORY POWER Signatory power alone by Palm, Christoph FINANCIAL YEAR Registered financial year: 0101 - 1231 DATE OF REGISTRATION OF CURRENT AND PREVIOUS BUSINESS NAMES 2021-11-29 Avient S.à r.l., Sweden Filial 2018-08-28 PolyOne S.à.r.l., Sweden Filial INFORMATION ABOUT THE FOREIGN COMPANY B226205 Avient S.á.r.l. 19, Route de Bastogne L-9638 Pommerloch LUXEMBURG Registered office of the foreign company: Pommerloch Name of the register in which the foreign company is registered: e-Certificate of registration Swedish Companies Registration Office BRANCH D1a- 6858922 Registration number Date of registration of the company Document created on Date of registration of current name Page 516411-5031 2018-08-28 2021-11-30 17:11 2021-11-29 3 (3) RCS, Registre de Commerce, Luxembourg Business Register LUXEMBURG Foreign company's financial year: 0101 - 1231 The above information is an extract from the Trade and Industry Register Bolagsverket, the Swedish Companies Registration Office.

ECert - 2024-03-22T104613.866.pdf Page 1 of 53 Validity of this certificate is based on the successful completion of the periodic surveillance audits of the management system defined by the above scope and is contingent upon prompt,written notification to ABS Quality Evaluations, Inc. of significant changes to the management system or components thereof. Dominic Townsend, President Effective Date: 22 March 2024 Expiration Date: 28 February 2025 Revision Date: 22 March 2024 Avient Corporation - Cota, Colombia Autopista Medellín Km 2.5, Via Parcelas Km 1 Vereda Siberia Cota, Cundinamarca 250017 Colombia Design and Manufacture of Colorants and Additives for Plastics 65536-116863Certificate No: Page 12 of 53 ABS Quality Evaluations ABS Quality Evaluations, Inc. 1701 City Plaza Drive, Spring, TX 77389, U.S.A. Dominic Townsend, President Effective Date: 22 March 2024 Expiration Date: 28 February 2025 Revision Date: 22 March 2024 Avient Pakistan (Private) Limited 1-A/1, Sector-20 Korangi Industrial Area Korangi, Sindh 74900 Pakistan Design and Manufacture of Colour and Additive Concentrates, Thermoplastic Resins and Specialty Compounds 65536-117317Certificate No: Page 20 of 53 ABS Quality Evaluations ABS Quality Evaluations, Inc. 1701 City Plaza Drive, Spring, TX 77389, U.S.A.

While traveling on company business, you are expected to: 1. Follow these two simple rules: 1. Ethics Hotline: https://www.Avient.com/company/policies-and-governance/ethics-hotline Telephone Ethics Hotline Number: 1-877-228-5410 https://www.Avient.com/company/policies-and-governance/ethics-hotline North America Global Headquarters Avon Lake, United States 33587 Walker Road Avon Lake, OH, United States 44012 Toll Free: +1 866 765 9663 Phone: +1 440 930 1000 Fax: +440 930 3064 Asia Pacific Regional Headquarters Shanghai, China 2F, Block C 200 Jinsu Road Pudong, 201206 Shanghai, China Telephone: +86 (0) 21 6028 4888 Fax: +86 (0) 21 6028 4999 South America Regional Headquarters Sao Paulo, Brazil Av.

Use of Non-GAAP Measures Page 3 -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Strategy and Execution Drive Results Page 4 All time closing high of $29.48 August 1, 2013 • 15 consecutive quarters of double digit EPS growth • 42% CAGR adjusted EPS expansion 2006-2012 • YTD stock price has increased 42% versus 20% growth in the S&P • 275% increase in market cap: $0.7b $2.6b since 2006 The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Four Pillar Strategy Page 5 PP&S 15% Specialty 60% Distribution 25% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010* 2011* 2012* 2015 Target Ad ju st ed E ar ni ng s P er S ha re Appliance 6% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 4% Consumer 9% Packaging 18% Industrial 10% Misc. 5% HealthCare 9% Transportation 16% Textiles 1% United States 70% Europe 14% Canada 8% Asia 5% Latin America 3% 2012 Revenues: $4.0 Billion* End Markets* 2012 Revenues: $4.0 Billion* EPS Page 6 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms & excludes discontinued operations PolyOne At A Glance * Restated to exclude discontinued operations Old PolyOne Transformation *Operating Income excludes corporate charges and special items **Pro Forma results include Spartech and Glasforms acquisitions, Specialty Coatings reclass and excludes discontinued operations 2% 34% 43% 45% 60% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2012 2012 PF** 2015 % o f O pe ra tin g In co m e* JV's PP&S Distribution Specialty Specialty OI $5M $46M $87M $114M $150M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 H1 2013 2015 Where we were Where we are Organic Consolidated Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.7% 12.6% 12 – 16% Global Specialty Engineered Materials 1.1% 10.9% 9.2% 12 – 16% Designed Structures & Solutions — — 4.4% 8 – 10% Performance Products & Solutions 5.4% 8.1% 8.2% 9 – 12% Distribution 2.6% 6.1% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 62% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 26% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 *Percentage of Specialty Platform revenue from products introduced in last five years 19.5% 46.5% 2006 Q2 2013 $20.3 $44.7 2006 TTM Q2'13 14.3% 31.1% 2006 Q2 2013 Research & Development Spending Specialty Platform Vitality Index Progression* Innovation Drives Earnings Growth ($ millions) Specialty Platform Gross Margin % Page 9 We are Experts in Polymer Science and Formulation  Polymer Science  Formulation  Chemistry  Processing Inputs  Base Resins  Additives  Modifiers  Colorants Specialized Polymer Materials, Services, and Solutions Expertise Satisfied Consumers PolyOne Customer Innovative Products & Services  Marketplace Demands  Performance Requirements  Value Drivers Page 10 Positioned for Strong Growth 2015 Target Rev: $5B Adj.

Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation Page 4 • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth • 17 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Steve Newlin Appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2013 2014 and beyond -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Russell 2000 Dow Jones Chemical All time high of $38.38 March 7th, 2014 • 17 consecutive quarters of double digit EPS growth • 49% CAGR adjusted EPS expansion 2006-2013 • 2013 stock price increased 73% versus 30% growth in the S&P • More than seven fold increase in market cap: $0.5b $3.6b Strategy and Execution Drive Results Page 5 Appliance 4% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 5% Consumer 10%Packaging 16% Industrial 12% HealthCare 11% Transportation 18% Misc. 2% United States 66% Europe 14% Canada 7% Asia 6% Latin America 7% PP&S 20% Specialty 53% Distribution 27% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 1.31 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010 2011 2012 2013 2015 Target Ad ju st ed E ar ni ng s P er S ha re 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion EPS Page 6 PolyOne At A Glance Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 2015 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty Specialty OI $5M $46M $87M $195M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 2013 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.2% 12 – 16% Global Specialty Engineered Materials 1.1% 9.3% 12 – 16% Designed Structures & Solutions -- 5.6% 8 – 10% Performance Products & Solutions 5.4% 7.2% 9 – 12% Distribution 2.6% 5.9% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 62% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.1% 15% 4) Adjusted EPS Growth N/A 31% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 Bridge To $2.50 Adjusted EPS By 2015 2015 EPS: $2.50 2013 EPS: $1.31 Mid single digit revenue CAGR Page 9 Mergers & Acquisitions Spartech accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Innovation Drives Earnings Growth $20.3 $52.3 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years Page 10 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Healthcare Consumer Packaging and Additive Technology Transportation Page 11 Unique and Innovative Solutions that Help Customers Win https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG Net Debt / EBITDA* = 1.8x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Significant Debt Maturities As of December 31, 2013 ($ millions) Page 12 Coupon Rates: 7.500% 7.375% 5.250% Debt Maturities & Pension Funding – 12/31/13 *TTM 12/31/2013 ** includes US-qualified plans only 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2013 Pension Funding** As of December 31, 2013 Free Cash Flow and Strong Balance Sheet Fund Investment •Targets that expand our: • Specialty offerings •End market presence •Geographic footprint •Operating Margin • Synergy opportunities •Adjacent material solutions •Expanding our sales, marketing, and technical capabilities • Investing in operational and LSS initiatives (including synergy capture) •Manufacturing alignment Organic Growth Share Repurchases Dividends Acquisitions Page 13 $0.16 $0.20 $0.24 $0.32 $0.00 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend • Repurchased ~5 million shares in 2013 • 15 million shares are available for repurchase under the current authorization The New PolyOne: A Specialty Growth Company 2015 Target: $2.50 Adjusted EPS Why Invest In PolyOne? Strong past performance demonstrates that our strategy and execution are working • Megatrends align with our strengths • Innovation and services provide differentiation, incremental pricing power, and competitive advantage • Strong and proven management team driving growth and performance • Addressable market exceeds $40 billion Page 14 1 Schedule I Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S. Appendix At a Glance�Global Specialty Engineered Materials At a Glance�Global Color, Additives, and Inks At a Glance�Designed Structures and Solutions At a Glance�Performance Products and Solutions At a Glance�Distribution Plastics: Key to Future Sustainable Development Establish Lean Six Sigma As Way of Life Application Examples Slide Number 24 2012 Range Rover Evoque Interior Slide Number 26 Slide Number 27 Metal Replacement Solutions High-Barrier Packaging Containers Aerospace Applications Sidoti Reconciliation of Non-GAAP.pdf Section 1

Use of Non GAAP Measures Page 3 -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Strategy and Execution Drive Results Page 4 All time closing high of $29.48 August 1, 2013 • 15 consecutive quarters of double digit EPS growth • 42% CAGR adjusted EPS expansion 2006-2012 • YTD stock price has increased 42% versus 20% growth in the S&P 400% increase in market cap, from $0.7b to $2.8b since 2006 The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Four Pillar Strategy Page 5 PP&S 15% Specialty 60% Distribution 25% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010* 2011* 2012* 2015 Target Ad ju st ed E ar ni ng s P er S ha re Appliance 6% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 4% Consumer 9% Packaging 18% Industrial 10% Misc. 5% HealthCare 9% Transportation 16% Textiles 1% United States 70% Europe 14% Canada 8% Asia 5% Latin America 3% 2012 Revenues: $4.0 Billion* End Markets* 2012 Revenues: $4.0 Billion* EPS Page 6 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms & excludes discontinued operations PolyOne At A Glance * Restated to exclude discontinued operations Old PolyOne Transformation *Operating Income excludes corporate charges and special items **Pro Forma results include Spartech and Glasforms acquisitions, Specialty Coatings reclass and excludes discontinued operations 2% 34% 43% 45% 60% 62% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2012 2012 PF** H1'13 2015 % o f O pe ra tin g In co m e* JV's PP&S Distribution Specialty Specialty OI $5M $46M $87M $114M $150M $98M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 H1 2013 2015 Where we were Where we are Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.6% 12 – 16% Global Specialty Engineered Materials 1.1% 9.2% 12 – 16% Designed Structures & Solutions -- 4.4% 8 – 10% Performance Products & Solutions 5.4% 8.3% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 62% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 26% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 *Percentage of Specialty Platform revenue from products introduced in last five years 11.5% 46.5% 2006 Q2 2013 $20.3 $44.7 2006 TTM Q2'13 14.3% 31.1% 2006 Q2 2013 Research & Development Spending Specialty Platform Vitality Index Progression* Innovation Drives Earnings Growth ($ millions) Specialty Platform Gross Margin % Page 9 We are Experts in Polymer Science and Formulation  Polymer Science  Formulation  Chemistry  Processing Inputs  Base Resins  Additives  Modifiers  Colorants Specialized Polymer Materials, Services, and Solutions Expertise Satisfied Consumers PolyOne Customer Innovative Products & Services  Marketplace Demands  Performance Requirements  Value Drivers Page 10 Positioned for Strong Growth 2015 Target Rev: $5B Adj.

Bir pozisyon için başvurduğunuz yerel Avient kuruluşunun yasal mercisi kişisel bilgileriniz konusunda veri denetleyicisi olarak hareket edecektir. 1. Bize Ulaşın Herhangi bir sorunuz varsa veya haklarınızı kullanmak isterseniz bize aşağıdaki adresten ulaşabilirsiniz: Kurumsal Gizlilik Yetkilisi Avient Corporation 33587 Walker Road Avon Lake, Ohio 44012 E-posta: PRIVACY.OFFICER@AVIENT.COM Telefon: 1-800-901-2078 mailto:PRIVACY.OFFICER@AVIENT.COM Gizlilik sorularınız veya taleplerinizi bize çevrimiçi formumuzu doldurarak da gönderebilirsiniz. Geçerlilik Tarihi: 1 Ağustos 2020 https://privacyportal.onetrust.com/webform/b25cf7b1-a93a-4d26-8c84-ceda4d0ae91b/e180cbe4-d1b9-49bd-b621-cb5f6a0f42cb mailto:PRIVACY.OFFICER@AVIENT.COM

One caveat: Typical TPE shrinkage is around 2% while that of substrate materials is closer to 1%. When looking to incorporate sustainable content into your TPE, the raw material cost may be more expensive than traditional materials for three reasons 1) supply chain maturity, 2) high demand, low supply, 3) location of source and supplier. WE’VE GOT YOU COVERED. http://www.art.canaco.org https://www.avient.com/sites/default/files/2020-11/gls-acqua-plose-case-study.pdf 1http://store.elsevier.com/Handbook-of-Polymer-Applications-in-Medicine- and-Medical-Devices/isbn-9780323221696/ Tear Resistance PERFORMANCE COMPARISON In Handbook of Polymer Applications in Medicine and Medical Devices,1 Laurence W.

主要特性 在三个通过ISO 13485认证的医疗生产线生 产全球统一的配方，提供全球一致性和供应 链保障 变更控制记录不限于CAS编号级别，降低变 更风险 • • 不含动物源性物质和邻苯二甲酸盐 可用作各种聚合物的母粒或即用型配方 为方便起见，可在一个产品中实现功能性和颜 色的组合 • • • 法规支持 经过预测试的原材料： - ISO 10993-1 - USP 第、章（VI类） - USP （指南），6.2.3 可萃取元素； USP - ICHQ3D/USP 2 可萃取金属 - 欧洲药典 3.1 聚烯烃（如适用） FDA发布的注册药品主文件（III类）和/或医疗 器械主文件 为符合（新）法规（如IVDR）的批准或过渡提 供文档支持 • • • 适用医疗保健使用限制—见下文。 在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。